CRISPR produces ‘life-altering’ changes, male allyship in medicine

October 21, 2021

1 min read

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The CRISPR/Cas9 gene-editing system is producing results that may transform the treatment of certain diseases, according to Nobel Prize winner Jennifer A. Doudna, PhD.

One of the best examples, she said, is for the treatment of sickle cell disease. A recap of her keynote address on CRISPR during the virtual AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics was the top story in hematology/oncology last week.

Photo of sickle cells
Source: Adobe Stock

Another top story covered a presentation at the Women in Medicine Summit, which outlined the importance of mentorship and male allyship of female physicians.

Read these and more top stories in hematology/oncology below:

CRISPR editing can produce ‘life-altering’ changes in patient health, Nobel laureate says

The CRISPR/Cas9 gene-editing system already is producing results that may fundamentally transform the treatment of certain diseases, according to one of the recipients of the 2020 Nobel Prize in Chemistry. Read more.

Male allyship of female physicians entails mentorship, equality at home

In his presentation at the Women in Medicine Summit, W. Brad Johnson, PhD, acknowledged the oddness of the fact that he and his co-presenter David G. Smith, PhD, were “two men at a women’s conference.” Read more.

Responses to COVID-19 vaccination vary after treatment for lymphoid malignancies

Patients with lymphoid malignancies who received anti-CD20 therapy within the previous year did not demonstrate antibody responses to the mRNA COVID-19 vaccines, according to study results published in Blood Advances. Read more.

FDA approves Tecentriq for new lung cancer indication

The FDA expanded the approval of Tecentriq (atezolizumab, Genentech/Roche) to include adjuvant treatment of certain patients with non-small cell lung cancer. Read more.

Tremelimumab-durvalumab regimen extends OS in unresectable HCC

The addition of MedImmune (tremelimumab/AstraZeneca) to first-line Imfinzi (durvalumab, AstraZeneca) significantly improved overall survival compared with sorafenib for certain patients with unresectable hepatocellular carcinoma, according to topline data released by the agent’s manufacturer. Read more.

Read more here: Source link